<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842595</url>
  </required_header>
  <id_info>
    <org_study_id>R NIMP</org_study_id>
    <nct_id>NCT00842595</nct_id>
  </id_info>
  <brief_title>Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas</brief_title>
  <official_title>Phase II Study of Treatment of Relapsed Agressive Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the protocol is to estimate the complete response rate of three
      courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone
      in relapsed aggressive non hodgkin's B-cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II study of the efficacy and toxicity of rituximab, navelbine, ifosfamide,
      mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell lymphoma.

      The study intervention is an administration of 3 courses of the abovementioned drugs, witch
      doses are detailed below. Remission is assessed and the investigator is free to proceed with
      any kind of consolidation , he decides best for the patient( high dose or standard
      chemotherapy).

      The addition of Rituximab the the NIMP protocol is warranted on the basis of previous
      publications wtich have shown a significant advantage in addition to chemotherapy in complete
      remission rate and in overall survival.

      Navelbine has shown an interesting activity in lymphoma relapse. Mitoxantrone has a good
      toxicity profile for patients who have prevously received anthracyclines, and there is not so
      much cross resistance between the two drugs.

      Ifosfamide is commonly used in the treatment of relapsed and refractory lymphoma, because of
      its low hematologic toxicity profile and good antitumor activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>CR AFTER 3 R NIMP COURSES</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall remission rate</measure>
    <time_frame>OS after 3 R NIMP COURSES</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>R NIMP TOLERANCE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomy</measure>
    <time_frame>treatment phramacoeconomy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R NIMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>6 courses every 28 days</description>
    <arm_group_label>R NIMP</arm_group_label>
    <other_name>(Mabthera ® )Rituximab IV 375 mg/m²day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>6 courses every 28 days</description>
    <arm_group_label>R NIMP</arm_group_label>
    <other_name>(Navelbine ®) Vinorelbine IV 25mg/m² day 1 and day 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>6 courses every 28 days</description>
    <arm_group_label>R NIMP</arm_group_label>
    <other_name>(Holoxan®)Ifostamide 1000mg/m² day 1 to day 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>6 courses every 28 days</description>
    <arm_group_label>R NIMP</arm_group_label>
    <other_name>(Novantrone®) Mitoxantrone 10mg/m² day1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>6 courses every 28 days</description>
    <arm_group_label>R NIMP</arm_group_label>
    <other_name>(Cortancyl®)Prednisone 1m/kg day 1 to day 5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders, between 18 and 75 years old

          -  CD 20+ large cell lymphoma

          -  In first relapse

          -  No previous autologous stem cell transplantation or relapsing more than 12 months
             after an autologous stem cell transplantation

          -  Ann Arbor stage I, II, III ou IV

          -  ECOG 0,1 or 2

          -  Signed informed consent

        Exclusion Criteria:

          -  age: before 18 and more than 75 years old

          -  other type of lymphoma

          -  Informed consent not signed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel GYAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed aggressive B-cell lymphoma</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

